AI assistant
AbbVie Inc. — Director's Dealing 2025
Jul 12, 2025
29755_dirs_2025-07-11_9117193b-af5b-4ad5-ba78-afb88c10d61d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2025-07-01
Reporting Person: AbbVie Inc. (EVP, Chief HR Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock, $0.01 par value | 7048 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (Right to buy) | $175.28 | 2034-02-14 | Common Stock (5043) | Direct | |
| Option (Right to buy) | $192.86 | 2035-02-12 | Common Stock (4687) | Direct |
Footnotes
F1: Includes 1,113 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 16, 2026, and include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 1,681 shares on 2/15/2025, and will become exercisable as to 1,681 shares on 2/15/2026 and as to 1,681 shares on 2/16/2027.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 1,563 shares on 2/13/2026, as to 1,562 shares on 2/13/2027 and as to 1,562 shares on 2/13/2028.